<DOC>
	<DOC>NCT00096603</DOC>
	<brief_summary>This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.</brief_summary>
	<brief_title>A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Previous participation in Study ACD2600g For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Moderate to severe plaque psoriasis</keyword>
</DOC>